Abstract
The results of the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST) study have been eagerly awaited by many involved in carotid interventions because of its randomized design, largest single trial sample size and the careful certification of experienced carotid surgeons and carotid interventionalists. There was no difference in the primary composite endpoint (of perioperative stroke, myocardial infarction [MI], or death and four-year ipsilateral stroke) between the carotid endarterectomy (n=1262) and carotid stenting groups (n=1240) who were treated for either symptomatic carotid stenosis >50% (n=1321), or asymptomatic stenosis >60% (n=1181) by angiography. The authors report up to four-year follow-up data from the CREST study showing a slightly higher periprocedural stroke rate after carotid stenting (4.1% versus 2.3%, p=0.01) and a slightly higher MI rate after endarterectomy (1.1% versus 2.3%, p=0.03). The difference in periprocedural stroke rate was primarily driven by the higher stroke rate in symptomatic patients undergoing carotid stenting (5.5% versus 3.2%, p=0.04), consistent with another recent trial involving only symptomatic patients {1}. A total of 96.1% of patients undergoing carotid stenting had use of an embolic protection device. Rates of ipsilateral stroke after the periprocedural period were equivalent between the two groups, showing that carotid stenting is a durable stroke prevention method at least for mid-term follow-up. Quality-of-life analysis at one-year revealed that stroke had a greater adverse effect than MI. Most interestingly, there was a significant interaction of age with the primary composite endpoint; specifically, younger patients fared better with stenting, whereas older patients fared better with endarterectomy, with the transition point at 70 years of age. The results of this trial demonstrate that carotid stenting has matched carotid endarterectomy in the composite primary endpoint and that CREST is likely to significantly affect clinical practice. However, these effects will take time as carotid stenting is regulated at several levels. Proponents of stenting argue that the primary endpoint was low and non-inferior with both therapies and that a first-generation stent and embolic protection device was used and that stenting results continue to improve. Proponents of endarterectomy argue that in terms of stroke, the outcome carotid intervention is supposed to prevent, endarterectomy remains superior. Proponents of modern medical therapy argue that it is sufficient for asymptomatic patients. However, the Asymptomatic Carotid Surgery Trial (ACST) has recently reported ten-year follow-up demonstrating the durability of carotid endarterectomy compared to medical management alone for patients with asymptomatic carotid stenosis. Given the large magnitude of stroke disability and costs, even small absolute risk reductions in stroke risk will have significant net health benefits. Further trials (Asymptomatic Carotid Trial [ACT]-1, ACST-2, Stent-Protected Angioplasty versus Carotid Endarterectomy [SPACE]-2) will contribute to defining the patient populations best treated with medical therapy alone, carotid endarterectomy and carotid stenting. Trial registration: NCT00004732